Physician
General Surgery
Dr. Melinda Mortenson, MD
|
|
Give Review
Doctor Melinda Mortenson, MD practices General Surgery. He researched medicine at University of California Davis School of Medicine. University of California Davis School of Medicine is ranked 43 in research and 19 in primary care medicine He has 2 awards "Meaningful Use Stage 1 Certification" and "Fellow (FACS)". Dr. Melinda Mortenson is a published MD. He has 17 publications published. The most current publication "Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?"
Publications
- Surgical strategies for synchronous coloRectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
- ERK/BCL-2 pathway in the resistance of pancreatic Cancer to anoikis.
- Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach.
- Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled t...
- Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography.
- Current diagnosis and management of unusual pancreatic Tumors.
- BCL-2 functions as an activator of the AKT signaling pathway in pancreatic Cancer.
- Comparison of two methods of future Liver remnant volume measurement.
- Total mesoRectal excision and pelvic node dissection for Rectal cancer: an appraisal.
- An Analysis of cost and clinical outcome in palliation for advanced pancreatic cancer.
- Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung Cancer.
- Targeting BCL-2 overexpression in various human Malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
- Immediate Breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvant chemotherapy is not delayed.
- Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung Cancer cell line.
- Proteasome inhibition with PS-341 (bortezomib) in lung Cancer therapy.
- Symptomatic Pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma).
Schools
University Of California Davis School Of Medicine
Procedures Preformed
- Adrenalectomy
- Appendectomy, Laparoscopic
- Appendectomy, Open
- Biopsy of Breast
- View All
Conditions Treated
- Abdominal Pain
- Anal and Rectal Cancer
- AnoRectal Abscess
- Appendicitis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
- Commercial Insurance Company
- Medicare Advantage PFFS
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Molina
- Tricare
- United Healthcare
Awards
- Meaningful Use Stage 1 Certification
- Fellow (FACS)
Education
-
University of California Davis -
University of California Davis School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Thomas C. Park, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos A. Perez, MD |
|
|
Dr. Joseph N. Young, MD |
|
|
Dr. Vijay P. Khatri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Philip D. Schneider, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Charles T. Brownridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tejveer S. Dhillon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie E. Dricken, MD |
|
|
Dr. Kevin M. Izquierdo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen S. Romanowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caitlin A. Smith, MD
This Doctor is OpenDoctor Recommended.
|